[
    [
        {
            "time": "2018-03-14",
            "original_text": "Cramer's lightning round: Hidden giant Cintas is one of my favorite names.",
            "features": {
                "keywords": [
                    "Cintas",
                    "favorite names"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Cramer's lightning round: Hidden giant Cintas is one of my favorite names.",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-14",
            "original_text": "AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down",
            "features": {
                "keywords": [
                    "AVEO Pharmaceuticals",
                    "Q4 Loss Widens",
                    "Shares Down"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-14",
            "original_text": "Merck's Keytruda Gets Priority Review for Cervical Cancer",
            "features": {
                "keywords": [
                    "Merck",
                    "Keytruda",
                    "Priority Review",
                    "Cervical Cancer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck's Keytruda Gets Priority Review for Cervical Cancer",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-14",
            "original_text": "What Happened with Merck’s Keytruda in 2017?",
            "features": {
                "keywords": [
                    "Merck",
                    "Keytruda",
                    "2017"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "What Happened with Merck’s Keytruda in 2017?",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-03-14",
            "original_text": "Your first trade for Wednesday, March 14",
            "features": {
                "keywords": [
                    "first trade",
                    "Wednesday",
                    "March 14"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Your first trade for Wednesday, March 14",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]